Results 151 to 160 of about 175,256 (310)
Abstract Introduction In border regions like the EuRegio Meuse‐Rhine (EMR), mobility does not stop at the border. HIV risk may therefore not only be determined by within‐country factors but also by between‐country differences. We explored between‐country differences in HIV indicators in the EMR using two complementary data‐driven approaches.
Hanne M. L. Zimmermann +9 more
wiley +1 more source
Introduction Long-acting injectable antiretroviral therapy (LAI-ART), especially cabotegravir plus rilpivirine, is primarily recommended as a switch option for virally suppressed individuals and may improve adherence, privacy, and treatment satisfaction.
Muhammad Wasay Shahid MPhil +9 more
doaj +1 more source
Abstract Objectives Bone health is negatively affected in people with HIV, and the risks of osteoporosis and fragility fractures are increased. The objective of this study was to describe the characteristics of those accessing bone health screening and identify factors associated with osteoporosis.
Rhys Nicholas +3 more
wiley +1 more source
Abstract Introduction Pregnant women with HIV are at risk of reduced engagement in HIV care during pregnancy and postpartum. Retention in care, defined as continuous engagement in HIV‐related treatment and follow‐up, is essential to achieve virological suppression and prevent vertical transmission.
Stine Hansen +3 more
wiley +1 more source
Abstract Objectives Japan's growing migrant population has increased the need for HIV services usable across linguistic, administrative and social circumstances. We reviewed evidence on access to HIV testing and care among people with migrant backgrounds and related non‐Japanese populations, focusing on movement into continuing care.
H. Nakamura, K. Yamaniha, K. Yamamoto
wiley +1 more source
This study aims to analytically explore the prevalence of oral manifestations in HIV-positive patients who are receiving or are not receiving highly active antiretroviral therapy (HAART).
Thais Suzigan Dagnoni +8 more
doaj +1 more source
Abstract Objectives Cardiovascular disease (CVD) is a major comorbidity and leading cause of morbidity and mortality in people with HIV (PWH). The REPRIEVE trial demonstrated that statin therapy significantly reduces cardiovascular events in PWH, prompting updated recommendations from major international societies.
Jasmini Alagaratnam +3 more
wiley +1 more source
Liver‐resident NK cells (CD49a+ NK cells) in rhesus macaques display distinct activating receptor and metabolic markers enhanced phenotype compared with hepatic NK cell subsets (CD49a−) in the liver. These cells exhibit heightened cytokine polyfunctionality with restrained cytotoxic responses upon mitogen stimulation in comparison with CD49a− NK cell ...
Andrew Hudson +4 more
wiley +1 more source
Abstract Background and Aims Antiretroviral therapy (ART) has modified the incidence of renal complications and the patterns of renal disease in people living with Human Immunodeficiency Virus (PLWH). We reviewed (2011–2021) the progress and outcomes (follow‐up to mid‐2025) of 158 such individuals.
Jacqueline A. Evans +5 more
wiley +1 more source
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani +16 more
wiley +1 more source

